Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by dt_coreon Feb 09, 2011 2:25pm

171 Views

Post# 18103423

RE: RE: RE: RE: Great

You are correct! Funny how I just finished writing my post and then my inbox shows me that Dundee has now also raised their target on HEM from $1.05 to $1.50. So all the bears on the name (Dundee, PI, and Fraser Mack) have now all thrown in the towl and increased their share prices.

From what I read on the Dundee report the only reason they are keeping an "underperform" is they are waiting until they see results before getting more bullish. In their words:

" We still believe in the Company's growth prospects and expect orders to rebound in 2011, but we are hesitant to raise our recommendation until 4Q10 results"

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!